Cite
MLA Citation
S. Denmeade et al.. “A phase II study of rapid cycling high dose testosterone (Bipolar Androgen Therapy) in men with metastatic castrate-resistant prostate cancer (mCRPC) resistant to abiraterone and/or enzalutamide.” European journal of cancer, vol. 69, n.d., pp. S15–. http://access.bl.uk/ark:/81055/vdc_100039473315.0x000036